Latest Director Appointments News

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Belararox Ltd announces the immediate resignation of founding Managing Director Arvind Misra, with Chairman Neil Warburton stepping in as interim leader during the search for a new executive director.

4DS Memory Limited has declared invalid a shareholder notice seeking to remove Executive Chairman David McAuliffe and other directors, rejecting calls for an extraordinary general meeting.

Aspermont Limited has appointed John Stark and David Straface as interim directors, reinforcing its board with seasoned insiders during a pivotal growth phase focused on data and intelligence services for global resource sectors.

Group One Capital Limited has adopted a comprehensive replacement Constitution at its 2025 Annual General Meeting, setting a refreshed governance framework aligned with current regulatory standards.

DevEx Resources has appointed Marnie Finlayson, a seasoned mining executive from Rio Tinto, as Managing Director starting December 2025, signaling a strategic push in uranium and rare earth projects.

Aspermont Limited’s shares have been suspended from trading due to a critical shortfall in board directors, raising questions about its governance and future compliance.

Develop Global Limited clarifies its director appointment and retirement process following an ASX compliance query, ensuring adherence to governance rules.

Besra Gold Inc. reported a $3.47 million loss for Q1 2026, weighed down by finance costs tied to a major gold purchase agreement. Despite asset impairments and net liabilities, management remains cautiously optimistic about ongoing funding and project development.

NEXTDC’s 2025 AGM highlights a landmark year with 42% growth in contracted utilisation and a $6.4 billion funding base, alongside strategic board changes and a new incentive plan to secure leadership.

Invex Therapeutics Ltd has been suspended from trading on the ASX due to a failure to maintain the minimum number of directors required by law. The suspension will remain until the company rectifies its governance structure and complies with listing rules.

Bentley Capital is seeking to recover 50% of legal costs from Keybridge Capital following a Federal Court ruling related to director William Johnson’s litigation expenses. Settlement talks are underway as the exact amount awaits judicial assessment.